subject: Chinese Colorectal Cancer Chemotherapy Has Made An Important Progress [print this page] Clinical research that whether Chinese patients with colorectal cancer are suitable for irinotecan combining with fluorouracil chemotherapy has made an important progress. The clinical study finds the suitable colorectal cancer patients for the use of irinotecan. This study has changed the Chinese clinical practice which does not dare to use irinotecan. It provides a scientific basis for patients with irinotecan topotecan chemotherapy to.
Irinotecan and leucovorin are the two main chemotherapy effective treatments for the advanced colorectal cancer. There are also essential programs. However, irinotecan chemotherapy Chinese Clinical rarely used, mainly due to international coverage irinotecan delayed diarrhea incidence higher. In the clinical studies, they carried out with irinotecan, have led to deaths due to severe delayed diarrhea. Thus, clinicians exists that the Iraqi legislature for side effects big misunderstanding and did not dare use, which makes the original treatment of colorectal cancer patients with limited treatment means more single.
To solve this problem, researchers has study on UGT1A gene polymorphism patients with colorectal cancer, healthy people and irinotecan toxicity relationship analysis. They found that the risk of side effects is not so great. Chinese populations use irinotecan and the Chinese people uses irinotecan adverse incidence is about 5%, the incidence of diarrhea was significantly lower than about 20% of the west. UGT1A gene SNP analysis found that more genotypes corresponding UGT1A enzymes were higher in the Chinese population distribution, which is SN38 inactivation of metabolic stronger, which may lead to SN38-induced toxicity in the population incidence the reasons for the lower. At the same time they found that the variation of the Chinese population and the variation of the docetaxel distribution of the Europe and the United States is not the same, this variation should be the main reason of the Chinese population with irinotecan diarrhea incidence is significantly lower.
Before using irinotecan drugs on colorectal cancer patients, people must first detect patients with gene variation. If any variation makes the occurrence of diarrhea, the doctor must do the appropriate adjuvant therapy preparation. If there is no variation, the likelihood of diarrhea occurrence is very small.
